Innate Pharma: Phase I Clinical Trial of IPH2102/BMS-986015 in

Innate Pharma: Phase I Clinical Trial of IPH2102/BMS-986015 in
Combination With Ipilimumab Announced 
A Phase I Study of the Anti-KIR Antibody IPH2102/BMS-986015 in
Combination With Ipilimumab in Patients With Selected Advanced Solid
Tumors Published on 
MARSEILLES, FRANCE -- (Marketwire) -- 12/19/12 --  Innate Pharma SA
(the "Company") (EURONEXT PARIS: IPH) (FR0010331421), the innate
immunity company developing first-in-class drugs for cancer and
inflammatory diseases, today announces that a second Phase I
combination trial for IPH2102/BMS-986015 was published on the NIH
This trial follows the Phase I trial of IPH2102/BMS-986015 in
combination with anti-PD-1 nivolumab (BMS-936558) announced in
October and published on the NIH website  
Marcel Rozencweig, Chief Medical Officer of Innate Pharma, said: "In
this second Phase I trial, IPH2102/BMS-986015 will be tested in a
variety of solid tumors, in combination with ipilimumab, the first
approved immunomodulating antibody." He added: "With the Phase II
trial in Acute Myeloid Leukemia and the Phase I in combination with
anti-PD-1 nivolumab previously announced, the anti-KIR approach is
undergoing wide early clinical testing". 
About the Phase I trial with IPH2102/BMS-986015 in combination with
ipilimumab in solid tumors:  
The purpose of this Phase I open label study is to determine whether
the combination of IPH2102/BMS-986015 and ipilimumab is safe and
provide preliminary information on the clinical activity of the
The primary outcome will be safety. Secondary outcomes will include a
preliminary assessment of efficacy, as measured by tumor assessment.
The study will be conducted in two parts -- dose escalation and
cohort expansion -- and is expected to enroll approximately 150
patients. Tumor types will be restricted to the following advanced
(metastatic and/or unresectable) tumor types: melanoma, non-small
cell lung cancer -- squamous and non-squamous histology, and castrate
resistant prostate cancer.  
About IPH2102/BMS-986015: 
IPH2102/BMS-986015 is a fully human monoclonal antibody blocking
interaction between Killer-cell immunoglobulin-like receptors (KIR)
on NK cells with their ligands. Blocking these receptors facilitates
activation of NK cells and, potentially, destruction of tumor cells
by the latter. 
IPH2102/BMS-986015 is licensed to Bristol-Myers Squibb Company (NYSE:
BMY). As part of the agreement between Innate Pharma and
Bristol-Myers Squibb, Bristol-Myers Squibb holds exclusive worldwide
rights to develop, manufacture and commercialize IPH2102/BMS-986015
and related compounds blocking KIR receptors, for all indications.
Under the agreement, Innate Pharma will conduct the development of
IPH2102/BMS-986015 through Phase II in Acute Myeloid Leukemia
IPH2102/ BMS-986015 is currently tested in a randomized,
double-blind, placebo-controlled Phase II trial in elderly patients
with AML in a maintenance setting as well as in two combination Phase
I trials in solid tumors, respectively with ipilimumab and with the
anti-PD-1 antibody nivolumab (BMS-936558). 
About Innate Pharma: 
Innate Pharma S.A. is a biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and inflammatory
The Company specializes in the development of new monoclonal
antibodies targeting receptors and pathways controlling the
activation of innate immunity cells. Its innovative approach has been
validated by licence agreements with two major pharmaceutical
companies, Novo Nordisk A/S and Bristol-Myers Squibb. 
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006,
Innate Pharma is based in Marseilles, France, and had 81 employees as
at September 30, 2012. 
Learn more about Innate Pharma at 
Practical Information about Innate Pharma shares:
 ISIN code:
 Ticker code: IPH 
This press release contains certain forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are subject
to numerous risks and uncertainties, which could cause actual results
to differ materially from those anticipated. For a discussion of
risks and uncertainties which could cause the company's actual
results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website ( or on Innate Pharma's website
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country. 
121219_IPH_Phase I trial ipilimumab  
For additional information, please contact: 
Innate Pharma 
Laure-Helene Mercier 
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87  
ATCG Press
Marielle Bricman
Mob.: +33 (0)6 26 94 18 53 
Press spacebar to pause and continue. Press esc to stop.